Acadia Resubmits US Application For Expanded Use In Alzheimer's Psychosis

 Acadia Pharmaceuticals Inc 

ACAD +0.15%

 (Get Free Alerts for ACAD) has resubmitted its FDA supplemental marketing application for pimavanserin for hallucinations and delusions associated with Alzheimer's disease psychosis (ADP).

• This resubmission responds to the FDA's Complete Response Letter (CRL) to the supplemental marketing application initially submitted for a proposed indication for pimavanserin for dementia-related psychosis. 
• The resubmission provides additional analyses from two previously conducted clinical studies, HARMONY1 and Study -0192, to support a proposed indication for ADP and is intended to address the issues raised in the FDA's CRL.

https://www.benzinga.com/general/biotech/22/02/25665925/acadia-resubmits-pimavanserin-us-application-for-expanded-use-in-alzheimers-psychosis